Shares of vaccine maker Moderna Inc. fell Wednesday as Goldman Sachs lowered its rating after the biotech's second cut to product revenue guidance in six months. Moderna shares (MRNA) fell 2% in ...

Adoption of Triple Combination Therapy Accelerates at Unprecedented Rates as Precision Medicine Revolution ContinuesRockville, MD, Jan. 29, 2025 (GLOBE NEWSWIRE) -- According to Fact.MR, a market ...

Moderna (NASDAQ:MRNA) shares about 3% ahead of Wednesday market open after Goldman Sachs cut its rating on the stock to Neutral from Buy.

Goldman Sachs analyst Salveen Richter downgraded Moderna (NASDAQ:MRNA) stock from Buy to Neutral, significantly reducing the price target to $51 from the previous $99. Trading at $44.94, the stock has ...

Despite continued underperformance in 2024, the biotech sector enters 2025 with a brighter outlook driven by groundbreaking ...

The Senate confirms Lee Zeldin to lead the E.P.A. The Justice Dept. seeks to have criminal charges dismissed against a former Republican representative. Trump signs Laken Riley Act, a law to make ...

An accounting provided by Hamas over the weekend confirmed intelligence assessments, Israeli officials said. By Isabel Kershner People were trampled as pilgrims at the Maha Kumbh Mela, one of ...

Bank of Canada cuts key rate 0.25% but warns of tariff uncertainty Bank of Canada cuts key rate 0.25% but warns of tariff uncertainty The quarter-point reduction marks a step down from the Bank of ...

Get dialed in every Tuesday & Friday with quick updates on the world of crypto ...